Elizabeth Budde, Associate Professor at City of Hope, shared a post by Toby Eyre, CLL specialist at the Oxford University Hospitals on X, adding:
“Our MS Michael Wang, Manali Kamdar, Sarit Assouline, Julio Chavez, Nilanjan Ghosh, Thomas Ollila, Daniel Hudson, Dipenkumar Modi, Mariana Bastos-oreiro, Seema Naik, Shania Nakhoda, Connie Batlevi is out. Pola-Mosun in 3L+ MCL: ORR 88%, CRR 79%.
Very tolerable in the OP setting.”
Quoting Toby Eyre‘s post:
“Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study.”
Title: Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study
Authors: Lihua E. Budde, Manali Kamdar, Sarit E. Assouline, Julio C. Chavez, Nilanjan Ghosh, Thomas A. Ollila, Daniel J. Hodson, Dipenkumar Modi, Mariana Bastos-Oreiro, Seema G. Naik, Shazia K. Nakhoda, Connie Lee Batlevi, Jue Wang, Sneha Makadia, Antonia Kwan, Elicia Penuel, Jing Jing, Hao Wu, Wahib Ead, Song Pham, Iris To, Michael C. Wei, Michael Wang
Other Articles Featuring Elizabeth Budde and Toby Eyre on OncoDaily.